CliffBio
small molecule

CEVIMELINE HYDROCHLORIDE

CEVIMELINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyZYDUS LIFESCIENCES GLOBAL FZE

Drug detail

Brand nameCEVIMELINE HYDROCHLORIDE
Active ingredientCEVIMELINE HYDROCHLORIDE
Strength30MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2026
Marketing statusRX

More from ZYDUS LIFESCIENCES GLOBAL FZE

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CEVIMELINE HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio